Clinical Development of imiquimod based immunotherapy
(KS01*)
Subject Area
Dermatology
Rheumatology
Term
from 2019 to 2023
Project identifier
Deutsche Forschungsgemeinschaft (DFG) - Project number 246807620
In the project we will develop an imiquimod based transcutaneous immunization method (TCI) and characterized mechanisms for T cell activation in mice. For clinical translation, we are conducting a study with the novel imiquimod formulation IMI-Gel in patients with actinic keratosis to investigate tolerability and local inflammatory reactions. The results will reveal the applicability of IMI-Gel in humans and demonstrate similarities and differences of imiquimod induced skin changes between mice and man. Our prospective aim is to conduct a TCI trial in humans with HPV infections.
DFG Programme
CRC/Transregios
